Form 4: Akero Therapeutics Executive Sells Shares to Cover Tax Obligations

Catriona Yale, Chief Development Officer of Akero Therapeutics, sold shares to cover tax withholding obligations related to vesting restricted stock units.

Summary

• On June 11, 2024, Catriona Yale, the Chief Development Officer of Akero Therapeutics, sold 2,825 shares of common stock.
• The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units.
• The shares were sold at a weighted-average price of $22.641, with individual transactions ranging from $22.640 to $22.760.
• Following the transaction, Yale directly owns 74,867 shares of Akero Therapeutics.
• The sale was automatic under the issuer's 'sell-to-cover' policy and not at the discretion of the reporting person.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to an executive's stock sale to cover tax obligations. It doesn't inherently convey positive or negative sentiment about the company's performance or future prospects.

Industry Context

Form 4 filings are a routine part of the US stock market, providing transparency into the transactions of company insiders. This particular filing reflects a common practice of executives selling shares to cover tax obligations related to equity compensation.

Key Dates